Medgenics Inc (NASDAQ:GNMX) – Investment analysts at Jefferies Group boosted their FY2018 earnings per share (EPS) estimates for Medgenics in a research report issued to clients and investors on Tuesday. Jefferies Group analyst M. Andrews now anticipates that the biotechnology company will post earnings per share of ($0.67) for the year, up from their prior estimate of ($0.82). Jefferies Group also issued estimates for Medgenics’ FY2019 earnings at ($1.26) EPS, FY2020 earnings at ($1.59) EPS and FY2021 earnings at ($1.35) EPS.
Medgenics (NASDAQ:GNMX) opened at $2.24 on Thursday. Medgenics has a one year low of $0.98 and a one year high of $6.18.
WARNING: This story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/02/17/jefferies-group-weighs-in-on-medgenics-incs-fy2018-earnings-gnmx.html.
Medgenics Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with MarketBeat.com's FREE daily email newsletter.